Isis antisense deal with Pantheco

ISIP licensed its Peptide Nucleic Acid (PNA) third-generation antisense chemistry to Pantheco (Copenhagen, Denmark) to treat diabetes and cardiovascular diseases. ISIP will receive $1.1 million in Pan...